The Top 5 Biosimilar Articles for the Week of June 27

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of June 27, 2022.

Number 5: Abstracts from the 2022 European Hematology Association (EHA) Congress presented positive data for 2 biosimilar candidates referencing Soliris (eculizumab): Amgen’s ABP 959 and Samsung Bioepis’ SB12.

Number 4: Having patients meet with a clinical pharmacist before a rheumatologist could help improve biosimilar adoption rates and mitigate the nocebo effect in patients with chronic diseases, according to a recent study.

Number 3: Formycon’s completed acquisition of 2 biosimilar assets and start of development for 2 others provided hope for investors as the company announced some expected losses during the first quarter of fiscal year 2022.

Number 2: The European Committee for Medicinal Products for Human Use (CHMP) recommended 2 biosimilars for approval: Celltrion Healthcare’s bevacizumab candidate and Formycon’s prospective ranibizumab product.

Number 1: Sarfaraz K. Niazi, PhD, a professor and biosimilar advocate, chronicled the current efforts to remove animal testing from application requirements for biosimilars under the Biologics Price Competition and Innovation Act (BPCIA), including recent congressional action.

To read all of these articles and more, visit centerforbiosimilars.com.